Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will estimate overall response rate of pemetrexed in poor risk patients with advanced, metastatic, or recurrent squamous cell carcinoma of the head and neck.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ohio State University Comprehensive Cancer Center
• Treatments: Pemetrexed

Criteria

Inclusion Criteria:

• Advanced, metastatic, or recurrent head and neck cancers

• Poor risk patients with ECOG performance status of 2

Exclusion Criteria:

• Prior treatment for recurrent or metastatic disease

• No clinical or radiological evidence of brain metatases

• Patients with bone only disease are not eligible

• Patients with pleural or peritoneal effusion as only manifestation of diesase